Efzofitimod 1.0 mg/kg or Placebo + Efzofitimod 3.0 mg/kg or Placebo + Efzofitimod 5.0 mg/kg or Placebo
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Sarcoidosis
Conditions
Pulmonary Sarcoidosis
Trial Timeline
Jan 29, 2019 → Jun 29, 2021
NCT ID
NCT03824392About Efzofitimod 1.0 mg/kg or Placebo + Efzofitimod 3.0 mg/kg or Placebo + Efzofitimod 5.0 mg/kg or Placebo
Efzofitimod 1.0 mg/kg or Placebo + Efzofitimod 3.0 mg/kg or Placebo + Efzofitimod 5.0 mg/kg or Placebo is a phase 1/2 stage product being developed by aTyr Pharma for Pulmonary Sarcoidosis. The current trial status is completed. This product is registered under clinical trial identifier NCT03824392. Target conditions include Pulmonary Sarcoidosis.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03824392 | Phase 1/2 | Completed |
Competing Products
20 competing products in Pulmonary Sarcoidosis